Attention Medical Professionals: A new pharmaceutical product, Bakcefort (Cefoperazone + Sulbactam), has been registered.
11.01.2018
Attention Medical Professionals: A new pharmaceutical product, Bakcefort (Cefoperazone + Sulbactam), has been registered.
Pharmaceutical Company "Kraspharma" Launches the Market's Most Recognized Parenteral Beta-Lactamase Inhibitor: Combination of Third-Generation Cephalosporin Cefoperazone with Irreversible Beta-Lactamase Inhibitor Sulbactam - Bakcefort.
This highly demanded medication among clinicians combines a broad antimicrobial spectrum with exceptionally high activity against both aerobic and anaerobic Gram-negative bacteria that produce beta-lactamases and are resistant to other antibiotics. It is also well-tolerated with a minimal risk of adverse drug reactions. Bakcefort is a monotherapy medication, eliminating the need for combinations of multiple antibiotics targeting different pathogens.
Bakcefort is indicated for the treatment of severe infections caused by mixed flora, in both children (starting from the neonatal period) and adults.
OJSC "Kraspharma" presents 4 dosages of Bakcefort, including those suitable for pediatric practice. Additionally, forms of the medication with a solvent will be available to healthcare professionals.
For detailed information about the pharmaceutical product Bakcefort, please follow the link.
This highly demanded medication among clinicians combines a broad antimicrobial spectrum with exceptionally high activity against both aerobic and anaerobic Gram-negative bacteria that produce beta-lactamases and are resistant to other antibiotics. It is also well-tolerated with a minimal risk of adverse drug reactions. Bakcefort is a monotherapy medication, eliminating the need for combinations of multiple antibiotics targeting different pathogens.
Bakcefort is indicated for the treatment of severe infections caused by mixed flora, in both children (starting from the neonatal period) and adults.
OJSC "Kraspharma" presents 4 dosages of Bakcefort, including those suitable for pediatric practice. Additionally, forms of the medication with a solvent will be available to healthcare professionals.
For detailed information about the pharmaceutical product Bakcefort, please follow the link.
